Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...
The Biden administration proposed a new rule Tuesday that would expand Medicare and Medicaid coverage of popular ...
Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of ...
Alladapt Immunotherapeutics, a well-financed biotech working in the food allergy field, shut down following talks with the ...
FDA extends review of Soleno Therapeutics' diazoxide choline extended-release tablets for Prader-Willi syndrome by three ...
Amgen’s long-anticipated weight loss data are here, with MariTide spurring an average of 20% weight loss after one year for ...
Roche's tiragolumab failed to meet overall survival endpoint in Phase 3 SKYSCRAPER-01 trial when combined with Tecentriq for ...
Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning.
JPMorgan's Morgan Health co-led an $80 million investment in Cortica, an autism care provider, marking its seventh investment ...
Aviceda seeks $200M for AVD-104 trial, Nerviano reacquires NMS-293 from Merck KGaA, MaaT Pharma reports positive Phase 1b ALS drug data, Secretome raises $20.4M, 35Pharma secures $35M Series C, ...
Agilent Technologies announced reorganization into three business units: life sciences and diagnostics led by Simon May, ...
Biohaven's Phase 3 trial of taldefgrobep alfa failed to meet its primary endpoint in spinal muscular atrophy, causing a 10% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback